A rare cause of otalgia is geniculate neuralgia. In its most typical f orm, it is charac terized by seve re paroxysmal neuralgic pain centered directly in the ear. The pain can be ofa gradual onset and ofa dull, persistent nature, but occasionally it is sharp and stabbing. When the pain becomes illtractabl e, all operation to surgically excise the nervus intermedius and geniculate ganglion via the middle cranial fossa approa ch is indicated. The pu rpose of this article is to review the long-term outcom es in 64 patients who were treated ill this manner. Findings indicate that excision of the nervus intermedius and geniculate ganglion call be routinely performed without causing fac ial paralysis and that it is an effective defi nitive treatmentfor intracta ble geniculate neuralgia.
Introduction
A rare ca use of severe intractable ea r pain is ge nic ulate neur algia, which is also ca lled tic douloureux of the ner vus intermedius. In its most typ ical form , geni cul ate neur algia is cha racterize d by se vere paro xysmal neuralg ic pain cent ered dir ectl y in the ea r. Th e pain can be of a gradual onse t and of a dull , persistent nature, but occasionally it is sharp and stabbing. In 197 6, the author described thi s cond ition in detail and pro pose d treatm ent by the exc ision of the ner vus intermedius and exc ision of the ge niculate ga ng lion via a middle cra nia l fossa appre ach .' Fifteen cases were reported.
It is the purp ose of this article to review the long-term outco mes in 64 patients who were treated betwee n 1966 and 1996 for ge niculate ne uralgia with exc isio n of the nervus interme dius and gen icu late ga ng lion. Fi ndings indi cate that exci sion of the ner vus intermediu s and genicul ate ganglion can co ntinue to be performed without causing fac ial paral ysis and that it is an effec tive, de finitive treatm ent for intrac table ge niculate neuralgia .
Diagnosis
Se nsa tion is supplied to the area of the ear by the V'", Vl l'", VIII'h, IX'h, and X'" cranial nerves and the 2 nd and 3 rd cer vical ner ves. It is imp ortant to know the area of distribution served by eac h of these nerves so that an acc urate diag nosis ca n be made. It is not uncommon to see an overlap, with invol vem en t of mo re than one cra nia l nerve. Th e overriding characterist ic of ge nicu late neu ral gia described by the patient is "a severe paroxysma l neuralgic pa in cen tere d directly in the ear." Th e pain was described by one patient as that which wo uld be ca use d by "an ice pick in the ear. " Th e pain does not ex tend int o the neck, into the face, or above the ear. Be fore a diagnosis of ge niculate ga nglio n neuralgia ca n be es tablished, all oth er possibl e causes of otalgia mu st be el imin ated . A thor ough neuro-otologic examination mu st be performed ; this examination should incl ude an aud iogra m for pur e tone s and speech, auditory evo ked respon se potenti als, and ves tibular tests, usu all y including alternate bilatera l bitherrnal ca loric testin g. In orde r to exclude other ca uses of the pain , all test res ults mu st be norm al. Likewise, find ings on magn etic resonance imagi ng (M RI) with ga do li ni um e nha nce me nt of th e e ntire bra in, ce rebellopontine ang le, and fac ial nerve mu st also be no rma l. Finall y, examinations of the nose, paran asal sinuses , mouth, teeth, nasopharynx, phary nx, and laryn x must reveal no ca use for the pain.
Surgical treatment
Th e specific surgica l treatm ent for ge niculate neuralgia is excision of the nervus inter me dius and the ge niculate ga ng lion via a middle cra nial fossa surg ical app roach (figure I). Thi s pro cedure was devi sed in 1966 , whe n it wa s found that exc ision of the nervus intermediu s alone d id not reli ably eliminate pain fro m the facial ner ve . It was clear that in so me (if not most) patient s, pa in fibers passin g fro m the ge niculate ga ng lion to the brain did so through the motor trun k of the VII'h nerve, as we ll as the nervu s interm ediu s. Anatomic dissections at that time sugges ted that most ganglion cells could be excise d by slicing away the ganglion fro m the internal genu of the fac ial nerve.
Th e surgica l technique involves exposure of the geniculate ga nglion, the greater petrosal nerve, and the facia l ne rve fr om th e cochlearifo rm pr ocess to th e cere bellopontine angle via the middl e cran ial fossa approach. Th e nervus intermedius is a clear-cut anatomic struc ture of approxi mately the same diameter as the chorda tymp ani nerve. It crosses ove r as a separate nerve fro m the superior vestibular nerve to the facial nerve. Th e nervus intermedius usually makes its exit fro m the inferior vestibular nerve at the poru s acusticus, where it then crosses diagonally as an indiv idual nerve for a length of 1 14 inch until it enters the fac ial nerve near the lateral end of the intern al auditory ca nal. It is usually best to firs t open the internal aud itory canal and excise a S-mm seg ment of the nervus intermed ius (figure 2).
Next, the area of the geniculate ganglion is addressed. It is know n from analysis of histologic sections and ganglion stains that the ganglion fibers lie anterior to the internal ge nu.J In additio n, because the nerve is circular, the ganglion cells form a concave attachment so that they extend for a short distance over the superior edge of the motor trunk of the faci al nerve and ove r the inferior edge of the facial nerve.J Gross ly, these anatomic determ inations are not visible. For thi s reason, it has been found effective to carefully identify surg ically the posterior edge of the motor trunk of the facial nerve at the genu as we ll as peripheral and proxim al to it for seve ral millimeters. A very sharp knife is used to cut away the ge nicu late ganglion fro m the internal genu of the facial nerve. Th e greater petrosal nerve stump is cut away so that a S-mm seg me nt is excised. In order to remov e an adequa te numb er of ganglion cells, it has been fo und that 30% of the anterio r porti on of the intern al ge nu .of the motor porti on of the fac ial nerve can be exc ised along with the ganglion wit hout cau sing a perma nent facial paraly sis (figure 3) . As with any facial nerve surge ry, the facial motor fibers must be handled delicately so that the remainin g mo tor fibers function nor mally and do not become ede matous.
Results
The study described in this article incl ude s the IS cases previously reported.' Betwee n 1966 and 1996,64 patients were treated wit h excisio n of the ner vus intermediu s and geniculate ganglion. Forty-e ight of these patients und erwent exc ision of the nervus intermedius and genic ulate ganglion alone, 13 had previously undergone a selec tive retro labyrinthine V" nerve sec tion, and three had undergone a selec tive retrolabyrinthine Vlh nerve section afte r exc ision of the nervus interme dius and geniculate ganglio n. Patients who underwent the co mbination procedures had co mplica ted cases of ear pain.
All patient s, with the exception of one whose etiology was Lyme disease, experienced excellent results with respect to relief of ear pain. No ne experienced a sustained hearing loss following surge ry, and none had a cerebrospinal fluid leak. Eleve n patients ex perienced a partial temp orary facial para lys is, and all recovered completely.
One patien t had a prolonged tempor ary facial paralysis, but this patient eve ntually experience d an exce lle nt recovery. Thi s patient had sustained the palsy as a result of a surgica l error. At the time of exposure of the greater petro sal nerve and gen iculate gang lion, it was not recognized that there was no bone ove r this area, a finding that is see n in 5% of patient s.' Consequently, excess ive ten- sion was place d on the grea ter petrosal nerve, which passed over to the internal genu and resulted in the facial palsy.
All 64 patients had a permanently non-crying eye on the involved side as a result of the excision of the greater petrosal nerve. This result is expec ted, and patients are apprised of it before surgery.
Case report
A white 47-year-old woman was referred for treatment of left ear pain of 2 years' duration. The pain had become increasi ngly more intense and more frequent. She reported that "the pain feels like an ice pick in the ear." The excrucia ting pain occ urred two or three times each day and lasted for 3 minutes at a time. In addition, she described a feeling of spasms in her left eyeli d, although none was visible upon exami nation at any time . Findings on comp uted tomography of the brain were normal. MRI with gado linium studies of the brain and facia l nerve showed no evidence of abnormality. Findings on physical examination of the ears , nose, and throat were completely normal. Vest ibular and audiome tric testing showed no evidence of neuro-otologic disease. Auditory evoked response and impedance audiometry were normal. A diagnosis of left gen iculate neuralgia was made.
On Sept. 7, 1994, a left middle cranial fossa surgica l approac h was used while the patient was under genera l anesthesia. A 3-inch temporal incision was made anterior and superior to the ear. A square of bone I V2 inch on each side was removed. The temporal lobe dura was elevated, and bone was removed from the grea ter petrosal nerve, geniculate gang lio n, internal genu, labyrinthine portion of the facial nerve, and upper portion of the internal auditory canal until a good view was obtained into the cerebellopontine ang le. The nervus intermedius was dissected from the superior vestib ular nerve at the porus acusticus and traced to its entry into the facia l nerve near the lateral end of the internal auditory canal. A 3-mm segment of this nerve was exc ised with scissors. A small piece of temporalis muscle was placed over the dural defect in the internal auditory cana l. Care was taken to identify the poster ior edge of the motor portion of the facia l nerve at the interna l genu and for several millimeters proximal and distal to this site. Using the posterior edge of the nerve as a guide, a sharp Beave r knife was used to exci se the genicu late ganglion and 25 % of the anterior portion of the motor part of the facial nerve at the internal genu .
The greater petro sal nerve was severed so that a l -cm segment of this nerve was excise d along with the geni culate ganglion. The dura was allowed to expand. The bone square was replaced, and the wound was close d in layers with interrupted subcutaneo us chromic catgut sutures. Electron microscopy of the geniculate gang lion revealed minimal nonspecific myelin sheath delamination (figure 4) .
The patient awoke from anesthesia and reported complete relief of her neu ralgic pain . Her postoperative cour se was uneventful, and she was discharged on the third postoperative day. Follow-up examination 2 years later revealed a complete and permanent relief of the neuralgic pain, normal facial function , no vertigo , no hearing loss, and no tinnitus. Before prescribing, please consult complete prescribing information ofwhichthefollowing isabrief summary, INDICATIONSAND USAGE Healing 01 ErosiveorUl cerative GastroesophagealRefluxDisease(GERD) ACIPHEX' isindicated for short-term (4to8weeks) treatment inthe healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD), for those patients who have not healed alter 8weeks of treatment, an additional 8-week course of ACIPHEX' may be conside red. MaintenanceofHealingotErosiveor UlceraliveGastroesophagealRefluxDisease (GERD) ACIPHEX' isindicated tormaintaining healing and reduction inrelapse ratesotheartburn symptoms inpatients witherosive orulcerative gastroesophageal refluxdisease (GERD Maintenance). Healing ofDuodenalUl cer s ACI PHEX' is indicated for short-term (up to four wee ks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within fou r weeks. 
Drug Interactions
Rabeprazole is metabolized bythe cytochrome P450(CYP450) drug metabolizing enzymesystem. Studies in healthy subjects have shown that rabepr azoledoes not have clinically significant interactionswit h other drugs metabolized bythe CYP450 system, such as wartarinand theophylline given as single oral doses, diazepam as a single intravenousdose, and phenytoingiven as asingle intravenous dose (With supplemental oral dosing). Invitro incubations employing human liver microsomes indicated that rabeprazoleinhibited cyclosporine metabolism with an I C~of62 micromolar, aconcentrationthat isover 50 times higher than the C~inhealthy volunteersfollowing 14 days ofdosingwith 20mg ofrabeprazole. This degree of inhibition is similar tothat byomeprazole atequivalent concentrations. Rabeprazole produces sustained inhibition ofgastric acidsecretion. An interaction with compounds which aredependent on gastric pH for absorption may occur due tothemagnitude ofacid suppression observed with rabeprazo' e. for example, in normai subjects, coadministration ofrabeprazoie20 mg DO resulted inan approximately 30%decrease inthebioavailabilityof ketoconazoieand increases in the AU Cand Cm.. tor digoxin of 19% and29%, respect ively. Ther efor e, patientsmay need tobe monitored when suchdrugs are taken concomitantl y with rabeprazole. Co-administration of rabeprazoleand antacids produced no clinically relevantchanges in plasma rabepr azol econcentrations. Carcinogenesis, Mut agenesis, Impairment ofFertility Ina88/ 104-weekcarcinogenicitystudy inCD-l mice, rabeprazoleat oral dosesup to10 0 mglkg/day di d not prod uce anyincreasedtumor occurrence. The hi ghest tested dose produced a systemic exposure to rabeprazole (AUC) of 1.40~g ' h r / mL whichis1.6timesthe humanexposure (plasma AUCQ-oo =0.88~g ' hr / mL ) atthe recommended dose forGERD (20 mg/day). Ina104-weekcarcinogenicitystudy inSprague-Dawley rats, males weretreat ed withoral doses of 5, 15,30 and 60 mglkg/day and females with5,15, 30, 60and120mglkg/day. Rabeprazol eprod uced gastric enterochromaffin-like (ECL)cell hyperplasiainmale andfemal eratsandECL cell carcinoid tum orsinfemale rats atalldoses incl U dingthelowest tested dose. The lowest dose (5 mglkg/day) produced asystemic exposure to rabeprazole (AUC) of about 0.1~g ' hr / m L which is about 0.1 times the human exposure at the recommended dose forGERD. Inmale rats, notreatment relat edtumorswe re observedat doses upto60mglkg/day produc ing arabepr azol eplasma exposure(AUC) ofabout 0.2~g ' hr /mL (0.2times thehuman exposureat the recommended dose for GERD). Rabeprazole was positive intheAmes test, the Chinesehamsterovary cell (CHOIHGPRT) forward gene mutation test and themouselymphomacell (L5178YITK+/-) forwardgenemutationtest. Itsdemethylated-metabolitewas also positive inthe Ames test. Rabepr azolewas negativeinthe in vitro Chinese hamster lung cell chromosome aberrationtest,the invivo mouse micr onucl eustest.and theinvivo and exvivo rat hepatocyte unscheduledDNA synthesis(UDS) tests Rabeprazole atintr avenousdoses upto30mglkg/day (plasma AUCof 8.8~g ' hr /m L , about10timesthe human exposure attherecommendeddose for GERD) was found tohave no effect onfertilityandreproductive pertormance ofmal eandfemalerats. Pre gnancy TeratogenicEll ecls, Pregnancy Category8: Ter atol ogyst udies havebeen pertormedinrat satintravenousdoses up to 50mglkg/day (plasma AUC of 11 .8~g ' h r /m L , about 13times the human exposure at the recommended dose for GERD) and rabbits atintr avenous doses up to30mglkg/day (plasma AUC of7.3~g ' hr /mL , about 8 timesthe human exposure atthe recommended dose for GERD) andhaverevealedno evi denceofimpairedfe rti lity orharmtothefet us duetorabeprazole. Ther eare, however , noadequate and well-controlledstudies inpregnant wo men. Becauseanimal reproduction studies are not always predictiveofhuman response, thisdrugshould be usedduring pr egnancyonlyifclearlyneeded. Nursing Mothers followingintravenousadministration of" C-Iabeledrabeprazoletolactating rats, radioactivityinmi lkreachedlevels thatwere2-to7-fold higher than levels inthe blood. It isnot knownif unmetabolized rabeprazoleis excreted in human breast milk. Administration of rabeprazol eto rats in late gestat ionand during lactation atdoses of 400 mglkg/day (about 195-times thehumandose based onmg/m') resul ted indecreasesin body weightgainof the pups. Since many drugs areexcreted inmi lk, and because ofthe potential foradverse reactions tonursing Infantsfromrabeprazole, adecision should be made todiscontinue nursing or discontinue the drug, taking into account the importance ofthe drugtothemother. Pediatr icUse Thesafety and effectiveness of rabeprazoleinpediatric patientshavenotbeenestablished.
Discussion
In cases of prim ary genic ulate neu ralgia uncomp licated by othe r types of pain , excision of the geniculate ga nglion and ner vus intermed ius via the middle cra nial fossa approach has prov ided reli abl e and precise result s. In cases where initi ally there are ove rla pping pains from more than one ner ve, the pati ent mu st be apprised that more than one procedure might be required.' Th e author has found that the two majo r ner ves involved in ear pain are the V'h and Vll" nerves. Th e nerve that see ms to ca use the maj or pain is usually attacked first. If necessary, surgery ca n be performed on the seco nd ner ve to relieve residu al pain. One patient who sustained a severe disabling blast injury to the ea r initiall y complained of pain right.in the ea r; excision of the genic ulate gang lion and ner vus inter medi us was successful in relieving this pain . As the patient began to fee l better, however, he complained of diffuse pain around the ea r; this pai n was compl etely relieve d I yea r later by selec tive retrolabyrinthine V'" nerve sec tion.
One elderly woman was re ferre d by a neurosu rgeon after she had had what was beli eved to be a co mp lete subocc ipital Vth nerve sec tio n. Even thou gh she had co mplete anes thesia of the right side of her face , she still co mplained of right ea r pain. She had total loss of right hearin g and ves tibular functi on and part ial facial pal sy with sy nki nes is. Exci sion of the ge niculate ganglion and ner vus interm ediu s was success ful in significa ntly allev iating her pain , although it did not eliminate it. Th e author su bseq uently used a translabyri nthine surgical approach to the cerebellopo ntine ang le and found that the sensory roo t of the V'h ner ve, although so mew hat distu rbed , was gross ly intact. Total incision of the senso ry bran ch of the nerve provid ed the patient with significant reli ef. She is not listed as having hearin g loss, vestibular loss, or parti al facial weakness because she ex perie nced no change following surge ry on the geniculate gang lion and all her findi ngs we re pre-existin g.
One of the most perpl exin g cases occu rred in a man 38 year s of age who had a docum ent ed history of seropos itive Lyme disease, after whi ch he developed left ea r pain that had persisted for 6 years. Th e nature and distribution of the pain were similar to those of genic ulate neuralgia. Th e patien t had been taking heavy doses of narco tics and was in a pai n-ma nage ment program. Excision of the geniculate ga nglion and ner vus intermediu s provided what see me d to be a 25 % rel ief of pain . Selecti ve retrolaby rinthine V" nerv e sec tion provid ed anothe r 50 % imp rovem ent , allowing the patient to get along on two hydrocod one tabl ets per day.
To the author 's know ledge , this treat men t has been utilized by only one other physician group. Dudley Weider, MD , at Th e Mary Hitch cock Clinic in Hanover, N .H., and co lleagues hav e per formed 23 proc edures of this type Volume 81, Number 1 (pe rsonal co mmunication, December 1996). A report of their experience treating patients wi th ear pai n was published in 1 9 91 .Õ ne imp ortant question co nce rns the anatomic site of the gang lio n cell s. I originally studied 100 temp oral bones and found a consistent anatomic distribution of the ganglio n ce lls within the geniculate ga ng lion attached to the anterior edge of the internal ge nu of the motor branch of the facia l ner ve confor ming to the tubular shape of the ner ve. I found that some of the ga ngl io n cells extended both superiorly and inferi orly to the anterior edge of the motor root. I reasoned that by exc ising a portion of the motor root, we would in turn remove the ganglion ce lls on this concave surface .
Rup a et al reported a study of the dissection of 11 hu man temporal bones and the distributio n of ga ng lion ce lls at the internal genu.' In one of their specimens, they found ex tens ion of cell bodies into the labyrinthin e segment of the facial nerve. In anoth er specimen, they found a sing le ga nglio n ce ll in the area of the genu, which led them to postul ate that the rem oval of the geniculate gang lion might not be effective in all pat ient s. Altho ugh this might be a potent ial probl em, from a practical sta ndpoint the 64 patie nts trea ted in this series (with the exception of the one patient with Lym e disease) have in fact achieved exemplary result s. Additional anat omi c studies are requ ired to cla rify the nature of this anatom ic var iatio n.
In co nclusion, physicians who dea l wi th pain in the ear and the head must be awa re of the characteristics of all neuralgic pain s and the anatomic distributio n of the ner ves innervating the area. Sometim es multiple ner ves mu st be exc ised. Th ese pro cedures can be pe rform ed with out ca usi ng perm anent facial paral ysis, hear ing loss, or ves tibu lar loss. Th ese methods offer relief for patients wi th intractable ea r pa in.
